المؤلفون: Arias-Martinez A; Doctoral Program in Pharmacy, Universidad de Granada, Barrio Verxeles n°13 2°, CP 27850, Granada, Viveiro, Spain. arantxa.91.am@gmail.com., Martínez de Castro E; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Gallego J; Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain., Arrazubi V; Medical Oncology Department, Hospital Universitario de Navarra, IdiSNA, Pamplona, Spain., Custodio A; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC, CB16/12/00398, Madrid, Spain., Fernández Montes A; Medical Oncology Department, Complejo Hospitalario Universitario de Orense, Orense, Spain., Diez M; Medical Oncology Department, Hospital Universitario Vall d'Hebron, VHIO, Barcelona, Spain., Hernandez R; Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain., Limón ML; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain., Cano JM; Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., Vidal-Tocino R; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca - IBSAL, Salamanca, Spain., Macias I; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain., Visa L; Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain., Martin Richard M; Medical Oncology Department, Instituto Catalán de Oncología (ICO), L'Hospitalet de Llobregat, Barcelona, Spain., Sauri T; Medical Oncology Department, Hospital Clinic, Barcelona, Spain., Hierro C; Medical Oncology Department, Instituto Catalán de Oncología (ICO)-Badalona, Barcelona; Badalona-Applied Research Group in Oncology (B-ARGO), Badalona, Spain., Gil M; Medical Oncology Department, Hospital General Universitario de Valencia-Ciberonc CB16/12/0035, Valencia, Spain., Cerda P; Medical Oncology Department, Hospital Universitario Santa Creu y Sant Pau, Barcelona, Spain., Martínez Moreno E; Medical Oncology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain., Martínez Lago N; Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain., Mérida-García AJ; Medical Oncology Department, Complejo Asistencial de Zamora, Zamora, Spain., Gómez González L; Medical Oncology Department, Hospital General Universitario de Alicante, Alicante, Spain., García Navalón FJ; Medical Oncology Department, Hospital Universitario de Son Llatzer, Mallorca, Spain., Ruiz Martín M; Medical Oncology Department, Complejo Asistencial Universitario de Palencia, Palencia, Spain., Marín G; Medical Oncology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain., López-López F; Medical Oncology Department, Hospital Universitario del Sureste, Madrid, Spain., Ruperez Blanco AB; Medical Oncology Department, Hospital Universitario de Toledo, Toledo, Spain., Fernández AF; Medical Oncology Department, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain., Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Carmona-Bayonas A; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain., Alvarez-Manceñido F; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Jul; Vol. 26 (7), pp. 1674-1686. Date of Electronic Publication: 2024 Feb 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Adenocarcinoma*/drug therapy , Adenocarcinoma*/pathology , Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/pathology , Fluorouracil*/therapeutic use , Fluorouracil*/administration & dosage , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/pathology , Capecitabine*/therapeutic use , Capecitabine*/administration & dosage , Receptor, ErbB-2*/metabolism , Registries* , Leucovorin*/therapeutic use , Leucovorin*/administration & dosage , Leucovorin*/adverse effects , Oxaliplatin*/therapeutic use , Oxaliplatin*/administration & dosage , Cisplatin*/therapeutic use , Cisplatin*/administration & dosage, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Organoplatinum Compounds/therapeutic use ; Organoplatinum Compounds/administration & dosage ; Progression-Free Survival ; Esophagogastric Junction/pathology ; Aged, 80 and over ; Spain

SCR Protocol: Folfox protocol

المؤلفون: Giustozzi M; Internal Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy., Connors JM; Brigham and Womens's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Ruperez Blanco AB; Medical Oncology Service, Complejo Hospitalario de Toledo (Castilla-La Mancha), Toledo, Spain., Szmit S; Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland., Falvo N; Service d'Exploration Vasculaire et de Phlébologie Interventionnelle, CHU Dijon, Dijon, France., Cohen AT; Guy's and St Thomas' NHS Foundation Trust, Hospital, King's College London, London, UK., Huisman M; Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands., Bauersachs R; Department of Vascular Medicine, Klinikum Darmstadt, Darmstadt, Germany., Dentali F; Department of Medicine and Surgery, Insubria University, ASST Settelaghi, Varese, Italy., Becattini C; Internal Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy., Agnelli G; Internal Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy.

المصدر: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2021 Nov; Vol. 19 (11), pp. 2751-2759. Date of Electronic Publication: 2021 Jul 29.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101170508 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7836 (Electronic) Linking ISSN: 15387836 NLM ISO Abbreviation: J Thromb Haemost Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms*/complications , Venous Thromboembolism*/diagnosis , Venous Thromboembolism*/drug therapy , Venous Thromboembolism*/epidemiology, Anticoagulants/adverse effects ; Dalteparin/adverse effects ; Hemorrhage/chemically induced ; Humans ; Neoplasm Recurrence, Local